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Abstract 
Background: The GetGoal-L-Asia and -S trials were multi-center trials conducted in 4 and 16 countries, respectively 
including Japan that evaluated the efficacy and safety of lixisenatide add-on treatment vs. placebo among patients 
with type 2 diabetes. The aims of this study were to determine the efficacy and safety of lixisenatide add-on treatment 
among Japanese patient groups.
Methods: All Japanese intent-to-treat patients with baseline and endpoint HbA1c measurements were included in 
the meta-analyses. Subgroup analyses were carried out for patients with low (<8 %) and high (≥8 %) baseline HbA1c 
levels, low (<25 kg/m2) and high (≥25 kg/m2) baseline body mass index (BMI), short (<10 years) and long (≥10 years) 
durations of diabetes, and for those <65 and ≥65 years of age.
Results: The overall study population of Japanese type 2 diabetes patients included 143 patients (mean age: 
59.0 years; 35 % female) treated with lixisenatide and 136 patients treated with placebo (mean age: 57.8 years; 32 % 
female). Among the subgroups, lixisenatide treatment vs. placebo was associated with greater change in HbA1c 
(Low HbA1c −0.80 %, p < 0.0001; High HbA1c −1.19 %, p < 0.0001; low BMI −0.88 %, p < 0.0001; high BMI −1.28 %, 
p < 0.0001; short diabetes duration −1.28 %, p < 0.0001; long diabetes duration −0.93 %, p < 0.0001; <65 years: 
−1.00 %, p < 0.0001; ≥65 years −1.24 %, p < 0.0001). Additionally, among the subgroups, lixisenatide treatment vs. 
placebo was associated with greater change in post-prandial glucose.
Conclusions: For Japanese type 2 diabetes patients lixisenatide may be an efficacious and safe add-on therapy lead-
ing to improved glycemic outcomes.
GetGoal-L-Asia NCT01169779
GetGoal-S NCT00713830
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Background
Type 2 diabetes is a metabolic disease resulting from 
insulin resistance and progressive beta-cell dysfunction. 
Its prevalence has increased worldwide in recent dec-
ades, and in Japan has increased from 6.9 million in 1997 
to 9.5 million in 2012 making it a priority for the Japa-
nese Ministry of Health, Labour and Welfare [1–4]. Some 
studies have reported differences in the pathophysiology 
of type 2 diabetes between Japanese patients and Cauca-
sian patients, with that of Japanese patients being more 
related to reduced insulin secreting capacity than insulin 
resistance [5, 6]. However, a recent study reported that 
the differences in insulin sensitivity and beta-cell func-
tion between Japanese and Caucasians are no longer sig-
nificant when differences in body mass index (BMI) and 
adipose tissue distribution are taken into consideration 
[7]. A World Health Organization expert review con-
cluded that compared with Caucasians the risk for type 
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Glucagon-like peptide-1 (GLP-1) receptor agonists, includ-
ing exenatide, liraglutide, dulaglutide, and lixisenatide are 
efficacious for the treatment of type 2 diabetes [9–13]. In 
addition to having glycemic efficacy, this class of drugs 
has other advantages such as the promotion of satiety and 
weight loss [9]. The GetGoal-L-Asia (NCT01169779) and -S 
(NCT00713830) trials were multicenter, multi-country trials 
that evaluated the efficacy and safety of lixisenatide add-on 
treatment vs. placebo among patients with type 2 diabetes 
with both trials having the primary endpoint of change in 
HbA1c [10, 11]. The GetGoal-L-Asia trial included 154 
patients treated with lixisenatide (10 μg for 1 week, 15 μg for 
1 week, then 20 μg once daily) and 157 patients treated with 
placebo from Japan, the Republic of Korea, Taiwan, and the 
Philippines [10]. All patients were also treated with basal 
insulin (glargine, detemir, NPH, premix) and ~70  % were 
also using a sulfonylurea drug [10]. The mean change at trial 
endpoint (24 weeks) in HbA1c was −0.77 % for lixisenatide 
treated patients and +0.11  % for placebo treated patients 
(treatment difference −0.88 %, p < 0.0001) [10]. Lixisenatide 
was also associated with significant decreases vs. placebo in 
7-point self-monitored plasma glucose level, fasting plasma 
glucose (FPG) level, and daily basal insulin dose [10]. The 
GetGoal-S trial included 570 patients treated with lixisenatide 
(10 μg for 1 week, 15 μg for 1 week, then 20 μg once daily) and 
286 patients treated with placebo from 16 different countries 
[11]. All patients in the GetGoal-S trial were also treated with 
a sulfonylurea drug and ~85  % were also using metformin 
[11]. The mean change at trial endpoint (24 weeks) in HbA1c 
was −0.85  % for lixisenatide treated patients and −0.10  % 
for placebo treated patients (treatment difference: −0.74 %, 
p  <  0.0001) [11]. Both GetGoal-L-Asia and GetGoal-S tri-
als included patients from Japan [10, 11]. The objectives of 
this study were to conduct meta-analyses of GetGoal-L-Asia 
and -S trial data to determine the efficacy and safety of lixi-
senatide add-on treatment among specific Japanese type 2 
diabetes patient groups, including those with low (<8  %) 
and high (≥8  %) baseline HbA1c levels, low (<25  kg/m2) 
and high (≥25  kg/m2) baseline BMI, short (<10  years) and 




All modified intent-to-treat Japanese patients living in 
Japan from the GetGoal-L-Asia and -S trials with base-
line and endpoint HbA1c measurements reported were 
included in the meta-analyses. Analyses were carried 
out for subgroups with low (<8 %) and high (≥8 %) base-
line HbA1c levels, low (<25  kg/m2) and high (≥25 kg/
m2) baseline BMI, short (<10 years) and long (≥10 years) 
durations of diabetes, and those <65 and ≥65  years of 
age.
Ethics statement
The GetGoal-L-Asia and -S trials were approved by the 
local ethics committee or institutional review boards and 
complied with the Declaration of Helsinki and the Inter-
national Conference on harmonization—good clinical 
practice guidelines and all applicable amendments [10, 
11].
Meta‑analyses method
The efficacy and safety of lixisenatide add-on treatment 
vs. placebo for different Japanese patient subgroups were 
evaluated by performing meta-analyses on the data from 
the clinical trials. For each efficacy outcome, including 
changes in HbA1c, weight, FPG, and post-prandial glu-
cose (PPG, standardized 2-h meal test), the mean changes 
in baseline to endpoint measurements for the lixisena-
tide and placebo treatment arms of each subgroup were 
used. Other outcomes evaluated during the trial peri-
ods included the likelihoods of symptomatic and severe 
hypoglycemia, the likelihood of achieving an endpoint 
HbA1c <7 %, and the likelihoods of achieving the follow-
ing composite endpoints: an endpoint HbA1c <7 % and 
no weight gain, an endpoint HbA1c <7 % and no symp-
tomatic hypoglycemia, and an endpoint HbA1c <7 % and 
no weight gain and no symptomatic hypoglycemia.
Meta-analysis outcomes were assessed using a random 
effects model. Weighted mean differences with 95 % con-
fidence intervals (CI) were determined for continuous 
data using the inverse variance method. Mantel–Haen-
szel odds ratios for 95  % CI were determined for all 
dichotomous outcome data. Heterogeneity between tri-
als was assessed by χ2 test. All meta-analyses were con-
ducted using Review Manager (RevMan, version 5.1, 
Copenhagen: Cochrane Collaboration). A p value of 0.05 
was used to determine the level of statistical significance.
Other summary statistics
The summary statistics of patient clinical characteristics 
as well as efficacy and safety outcomes for each treat-
ment arm within the study groups were determined. The 
treatment arms within each subgroup were compared to 
each other with p values calculated using a Chi square 
test or ANOVA test where appropriate. A p value of 0.05 
was used to determine the level of statistical significance. 
All descriptive statistical analyses were carried out using 
SAS® 9.3 (Cary, NC).
Results
The overall study population of Japanese type 2 diabe-
tes patients included 143 patients (mean age: 59.0 years; 
35  % female) treated with lixisenatide and 136 patients 
treated with placebo (mean age: 57.8 years; 32 % female). 
The mean durations of type 2 diabetes were 11.9 and 
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12.4  years among patients treated with lixisenatide and 
placebo, respectively. Lixisenatide treated patients had 
significantly greater changes in HbA1c (−1.08  %, confi-
dence interval (CI) −1.29, −0.86, p  <  0.0001) and PPG 
levels (−149.8  mg/dL, CI −170.4, −129.2, p  <  0.0001) 
in comparison to placebo treated patients during trial 
periods. Lixisenatide treated patients had a greater 
likelihood of having symptomatic hypoglycemia dur-
ing the trial periods in comparison to placebo treated 
patients [odds ratio (OR) 3.0, CI 1.4, 6.3, p  =  0.0040]; 
however, lixisenatide treated patients had greater likeli-
hoods of achieving an endpoint HbA1c <7  % (OR 20.3, 
CI 6.1, 67.8, p  <  0.0001), and the composite endpoints 
of an HbA1c <7 % and no weight gain (OR 13.5, CI 4.0, 
45.6, p < 0.0001), an HbA1c < 7 % and no symptomatic 
hypoglycemia (OR 18.5, CI 4.3, 78.8, p < 0.0001), and an 
HbA1c <7  % and no weight gain and no symptomatic 
hypoglycemia (OR 12.8, CI 2.9, 55.7, p = 0.0007) in com-
parison to placebo treated patients. Severe hypoglycemia 
was not observed among the overall study population of 
Japanese type 2 diabetes patients.
Baseline characteristics of study subgroups are pre-
sented in Table 1. Figure 1 presents a forest plot of mean 
treatment differences of changes in HbA1c during trial 
periods of Japanese type 2 diabetes patient subgroups.
Subgroups: Japanese type 2 diabetes patients with low 
(<8 %) and high (≥8 %) baseline HbA1c levels
A summary of the meta-analysis outcomes of Japanese 
type 2 diabetes patients with low (<8 %) and high (≥8 %) 
baseline HbA1c levels placebo is presented in Table  2. 
Lixisenatide treated patients with low (<8  %) base-
line HbA1c had significantly greater changes in HbA1c 
(−0.80  %, CI −1.18, −0.43, p  <  0.0001) and PPG levels 
(−132.0 mg/dL, CI −171.7, −92.4, p < 0.0001) in compar-
ison to placebo treated patients with low (<8 %) baseline 
HbA1c during trial periods. The likelihood of sympto-
matic hypoglycemia occurring during trial periods was 
not significantly different among patients with low (<8 %) 
baseline HbA1c treated with lixisenatide and placebo. 
Lixisenatide treated patients with low (<8  %) baseline 
HbA1c had greater likelihoods of achieving an endpoint 
HbA1c <7 % (OR 25.5, CI 5.2, 124.6, p < 0.0001), and the 
composite endpoints of an HbA1c <7  % and no weight 
gain (OR 15.8, CI 3.3, 75.8, p = 0.0005), an HbA1c <7 % 
and no symptomatic hypoglycemia (OR 11.8, CI 2.0, 68.7, 
p  =  0.0060), and an HbA1c <7  % and no weight gain 
and no symptomatic hypoglycemia (OR 8.9, CI 1.5, 52.2, 
p = 0.0154).
Lixisenatide treated patients with high (≥8  %) 
baseline HbA1c had significantly greater changes in 
HbA1c (−1.19  %, CI −1.46, −0.92, p  <  0.0001), FPG 
(−14.7  mg/dL, CI −25.9, −3.6, p  =  0.0097), and PPG 
levels (−162.0  mg/dL, CI −185.9, −138.1, p  <  0.0001) 
in comparison to placebo treated patients with high 
(≥8  %) baseline HbA1c during trial periods. Lixisena-
tide treated patients with high (≥8  %) baseline HbA1c 
had a greater likelihood of having symptomatic hypo-
glycemia during the trial periods in comparison to pla-
cebo treated patients (OR 2.9, CI 1.2, 7.1, p  =  0.0229); 
however, lixisenatide treated patients had greater likeli-
hoods of achieving an endpoint HbA1c <7  % (OR 15.8, 
CI 2.9, 85.6, p =  0.0014), and the composite endpoints 
of an HbA1c <7 % and no weight gain (OR 10.0, CI 1.8, 
55.9, p =  0.0091), an HbA1c <7 % and no symptomatic 
hypoglycemia (OR 11.1, CI 2.0, 61.8, p  =  0.0059), and 
an HbA1c <7 % and no weight gain and no symptomatic 
hypoglycemia (OR 6.4, CI 1.1, 38.6, p = 0.0430) in com-
parison to placebo treated patients with high (≥8  %) 
baseline HbA1c.
Subgroups: Japanese type 2 diabetes patients with low 
(<25 kg/m2) and high (≥25 kg/m2) baseline BMI
A summary of the meta-analysis outcomes of Japanese 
type 2 diabetes patients with low (<25  kg/m2) and high 
(≥25 kg/m2) baseline BMI is presented in Table 3. Lixi-
senatide treated patients with low (<  25  kg/m2) base-
line BMI had significantly greater changes in HbA1c 
(−0.88  %, CI −1.21, −0.55, p  <  0.0001) and PPG levels 
(−147.9 mg/dL, CI −178.6, −117.3, p < 0.0001) in com-
parison to placebo treated patients with low (<25  kg/
m2) baseline BMI during trial periods. Lixisenatide 
treated patients with low (<25 kg/m2) baseline BMI had 
a greater likelihood of having symptomatic hypoglyce-
mia during the trial periods in comparison to placebo 
treated patients (OR 2.8, CI 1.1, 7.0, p =  0.0270); how-
ever, lixisenatide treated patients had greater likeli-
hoods of achieving an endpoint HbA1c <7  % (OR 11.2, 
CI 3.2, 39.7, p =  0.0002), and the composite endpoints 
of an HbA1c <7  % and no weight gain (OR 7.6, CI 2.1, 
27.9, p =  0.0024), an HbA1c <7 % and no symptomatic 
hypoglycemia (OR 9.6, CI 2.1, 43.7, p = 0.0036), and an 
HbA1c <7  % and no weight gain and no symptomatic 
hypoglycemia (OR 7.4, CI 1.6, 35.2, p = 0.0114) in com-
parison to placebo treated patients with low (<25 kg/m2) 
baseline BMI.
Lixisenatide treated patients with high (≥25  kg/m2) 
baseline BMI had significantly greater changes in HbA1c 
(−1.28  %, CI −1.81, −0.75, p  <  0.0001) and PPG levels 
(−151.5 mg/dL, CI −178.8, −124.3, p < 0.0001) in com-
parison to placebo treated patients with high (≥25  kg/
m2) baseline BMI during trial periods. Lixisenatide 
treated patients with high (≥25  kg/m2) baseline BMI 
had a greater likelihood of having symptomatic hypo-
glycemia during the trial periods in comparison to pla-
cebo treated patients (OR 4.2, CI 1.1, 15.7, p = 0.0362); 
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however, lixisenatide treated patients had greater likeli-
hoods of achieving an endpoint HbA1c <7  % (OR 23.6, 
CI 3.0, 183.6, p = 0.0025), and the composite endpoints 
of an HbA1c <7 % and no weight gain (OR 16.2, CI 2.1, 
127.2, p = 0.0083), an HbA1c <7 % and no symptomatic 
hypoglycemia (OR 15.6, CI 2.0, 123.7, p =  0.0093), and 
an HbA1c <7 % and no weight gain and no symptomatic 
hypoglycemia (OR 9.5, CI 1.2, 77.7, p = 0.0356) in com-
parison to placebo treated patients with high (≥25  kg/
m2) baseline BMI.
Subgroups: Japanese type 2 diabetes patients with short 
(<10 years) and long (≥10 years) durations of diabetes
A summary of the meta-analysis outcomes of Japanese 
type 2 diabetes patients with short (<10 years) and long 
(≥10 years) durations of diabetes is presented in Table 4. 
Lixisenatide treated patients with short (<10 years) dura-
tion of diabetes had significantly greater changes in 
HbA1c (−1.28 %, CI −1.65, −0.91, p < 0.0001) and PPG 
levels (−152.6  mg/dL, CI −182.0, −123.2, p  <  0.0001) 
in comparison to placebo treated patients with short 
(<10  years) duration of diabetes. Lixisenatide treated 
patients with short (<10  years) duration of diabetes 
had a greater likelihood of having symptomatic hypo-
glycemia during the trial periods in comparison to pla-
cebo treated patients (OR 5.2, CI 1.5, 18.7, p = 0.0107); 
however, lixisenatide treated patients had greater likeli-
hoods of achieving an endpoint HbA1c <7  % (OR 32.1, 
CI 4.2, 246.6, p = 0.0009), and the composite endpoints 
of an HbA1c <7 % and no weight gain (OR 22.5, CI 2.9, 
174.3, p = 0.0028), an HbA1c <7 % and no symptomatic 
hypoglycemia (OR 19.8, CI 2.6, 153.5, p =  0.0043), and 
an HbA1c <7 % and no weight gain and no symptomatic 
hypoglycemia (OR 11.6, CI 1.4, 93.3, p = 0.0213) in com-
parison to placebo treated patients with short (<10 years) 
duration of diabetes.
Lixisenatide treated patients with a long (≥10  years) 
duration of diabetes had significantly greater changes 
in HbA1c (−0.93  %, CI −1.18, −0.67, p  <  0.0001), FPG 
(−12.6  mg/dL, CI −24.9, −0.4, p  =  0.0438), and PPG 
levels (−147.9  mg/dL, CI −176.8, −119.0, p  <  0.0001) 
in comparison to placebo treated patients with long 
Table 1 Baseline characteristics of study subgroups
SD standard deviation; BMI body mass index
Lixisenatide Placebo p value Lixisenatide Placebo p value
Low (<8 %) baseline HbA1c High (≥8 %) baseline HbA1c
N 44 33 99 103
Age (years), mean (SD) 61.2 (9.1) 58.7 (11.3) 0.29 58.0 (10.9) 57.5 (11.3) 0.75
Female-N (%) 14 (31.8) 8 (24.2) 0.47 36 (36.4) 36 (35.0) 0.83
Duration of diabetes (years), mean (SD) 13.1 (8.0) 12.8 (10.0) 0.89 11.3 (7.3) 12.3 (7.4) 0.34
HbA1c (%), mean (SD) 7.53 (0.29) 7.52 (0.29) 0.86 8.88 (0.62) 8.90 (0.58) 0.81
Low (<25 kg/m2) baseline BMI High (≥25 kg/m2) baseline BMI
N 77 73 66 63
Age (years), mean (SD) 60.9 (8.9) 59.8 (10.9) 0.49 56.7 (11.7) 55.4 (11.4) 0.53
Female-N (%) 21 (27.3) 24 (32.9) 0.45 29 (43.9) 20 (31.8) 0.15
Duration of diabetes (years), mean, (SD) 12.4 (7.5) 14.1 (9.1) 0.22 11.2 (7.5) 10.5 (6.2) 0.56
HbA1c (%), mean (SD) 8.38 (0.81) 8.41 (0.73) 0.79 8.56 (0.84) 8.74 (0.84) 0.23
Short (<10 years) duration of diabetes Long (≥10 years) duration of diabetes
N 68 59 75 77
Age (years), mean (SD) 55.9 (11.3) 53.3 (10.4) 0.19 61.8 (8.9) 61.2 (10.8) 0.71
Female-N (%) 27 (39.7) 16 (27.1) 0.13 23 (30.7) 28 (36.4) 0.46
Duration of diabetes (years), mean (SD) 5.5 (2.8) 5.9 (2.2) 0.42 17.7 (5.5) 17.5 (7.2) 0.86
HbA1c (%), mean (SD) 8.52 (0.81) 8.64 (0.86) 0.43 8.41 (0.84) 8.50 (0.74) 0.46
<65 years of age ≥65 years of age
N 97 97 46 39
Age (years), mean (SD) 53.9 (8.6) 52.6 (8.8) 0.30 69.7 (3.9) 70.7 (4.2) 0.25
Female-N (%) 35 (36.1) 30 (30.9) 0.45 15 (32.6) 14 (35.9) 0.75
Duration of diabetes (years), mean, (SD) 10.4 (6.9) 10.5 (6.5) 0.92 14.9 (8.0) 17.2 (9.6) 0.24
HbA1c (%), mean (SD) 8.56 (0.83) 8.82 (0.78) 0.16 8.24 (0.87) 8.44 (0.74) 0.25
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(≥10  years) duration of diabetes. Lixisenatide treated 
patients with long (≥10  years) duration of diabetes had 
greater likelihoods of achieving an endpoint HbA1c <7 % 
(OR 8.9, CI 2.5, 31.9, p = 0.0008), and the composite end-
points of an HbA1c <7 % and no weight gain (OR 6.3, CI 
1.7, 23.3, p =  0.0057), an HbA1c <7  % and no sympto-
matic hypoglycemia (OR 9.0, CI 2.0, 41.1, p  =  0.0046), 
and an HbA1c <7  % and no weight gain and no symp-
tomatic hypoglycemia (OR 7.5, CI 1.6, 34.7, p = 0.0099) 
in comparison to placebo treated patients with long 
(≥10 years) duration of diabetes.
Subgroups: Japanese type 2 diabetes patients <65 
and ≥65 years of age
A summary of the meta-analysis outcomes of Japa-
nese type 2 diabetes patients <65 and ≥65  years of age 
is presented in Table  5. Lixisenatide treated patients 
<65  years of age had significantly greater changes in 
HbA1c (−1.00 %, CI −1.29, −0.72, p < 0.0001) and PPG 
levels (−138.1  mg/dL, CI −177.0, −99.2, p  <  0.0001) in 
comparison to placebo treated patients <65 years of age. 
The likelihood of symptomatic hypoglycemia occurring 
during trial periods trended to be greater for patients 
<65  years of age treated with lixisenatide than pla-
cebo, but did not reach significance (OR 2.3, CI 1.0, 5.6, 
p = 0.06). Lixisenatide treated patients <65 years of age 
had greater likelihoods of achieving an endpoint HbA1c 
<7  % (OR 13.1, CI 3.4, 50.7, p =  0.0002), and the com-
posite endpoints of an HbA1c <7 % and no weight gain 
(OR 8.4, CI 2.1, 33.8, p =  0.0026), an HbA1c <7  % and 
no symptomatic hypoglycemia (OR 14.0, CI 2.6, 76.8, 
p  =  0.0023), and an HbA1c <7  % and no weight gain 
and no symptomatic hypoglycemia (OR 7.8, CI 1.3, 45.6, 
p  =  0.0221) in comparison to placebo treated patients 
<65 years of age.
Lixisenatide treated patients ≥65 years of age had sig-
nificantly greater changes in HbA1c (−1.24 %, CI −1.55, 
−0.92, p  <  0.0001) and PPG levels (−166.5  mg/dL, CI 
Fig. 1 Forest plot of hba1c treatment differences among Japanese type 2 diabetes patient subgroups
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Table 2 Summary of  meta-analysis outcomes for  Japanese type 2 diabetes patients with  low (<8  %) and  high (≥8  %) 
baseline HbA1c levels
FPG fasting plasma glucose, PPG postprandial glucose
Outcome Effect  
estimate
95 % Confidence limits p value Effect 
estimate
95 % Confidence limits p value
Lower Upper Lower Upper




Change in HbA1c (%) −0.80 −1.18 −0.43 <0.0001 −1.19 −1.46 −0.92 <0.0001
Change in weight (kg) −0.62 −1.72 0.49 0.28 −0.17 −0.68 0.34 0.52
Change in FPG (mg/dL) −12.5 −30.9 5.8 0.18 −14.7 −25.9 −3.6 0.0097
Change in PPG: meal  
test (mg/dL)
−132.0 −171.7 −92.4 <0.0001 −162.0 −185.9 −138.1 <0.0001
Odds  
ratio
95 % Confidence limits p value Odds  
ratio
95 % Confidence limits p value
Lower Upper Lower Upper
Low (<8 %)  
baseline HbA1c
High (≥8 %)  
baseline HbA1c
Symptomatic hypoglycemia 2.9 0.8 10.0 0.10 2.9 1.2 7.1 0.0229
Severe hypoglycemia 0.0 0.0 0.0 – 0.0 0.0 0.0 –
Endpoint HbA1c <7 % 25.5 5.2 124.6 <0.0001 15.8 2.9 85.6 0.0014
Endpoint HbA1c <7 % and no 
weight gain
15.8 3.3 75.8 0.0005 10.0 1.8 55.9 0.0091
Endpoint HbA1c <7 % and no 
symptomatic hypoglycemia
11.8 2.0 68.7 0.0060 11.1 2.0 61.8 0.0059
Endpoint HbA1c <7 % and no 
weight gain and no  
symptomatic hypoglycemia
8.9 1.5 52.2 0.0154 6.4 1.1 38.6 0.0430
Table 3 Summary of  meta-analysis outcomes for  Japanese type 2 diabetes patients with  low (<25  kg/m2) and  high 
(≥25 kg/m2) baseline body mass index (BMI)
FPG fasting plasma glucose, PPG postprandial glucose
Outcome Effect  
estimate
95 % Confidence limits p value Effect  
estimate
95 % Confidence limits p value
Lower Upper Lower Upper
Low (<25 kg/m2)  
baseline BMI
High (≥25 kg/m2)  
baseline BMI
Change in HbA1c (%) −0.88 −1.21 −0.55 <0.0001 −1.28 −1.81 −0.75 <0.0001
Change in weight (kg) −0.38 −1.07 0.32 0.29 −0.28 −1.18 0.61 0.53
Change in FPG (mg/dL) −5.9 −19.1 7.5 0.39 −21.2 −45.8 3.5 0.09
Change in PPG: meal: test (mg/dL) −147.9 −178.6 −117.3 <0.0001 −151.5 −178.8 −124.3 <0.0001
Odds  
ratio
95 % Confidence limits p value Odds  
ratio
95 % Confidence limits p value
Lower Upper Lower Upper
Low (<25 kg/m2)  
baseline BMI
High (≥25 kg/m2)  
baseline BMI
Symptomatic hypoglycemia 2.8 1.1 7.0 0.0270 4.2 1.1 15.7 0.0362
Severe hypoglycemia 0.0 0.0 0.0 – 0.0 0.0 0.0 –
Endpoint HbA1c <7 % 11.2 3.2 39.7 0.0002 23.6 3.0 183.6 0.0025
Endpoint HbA1c <7 % and no weight gain 7.6 2.1 27.9 0.0024 16.2 2.1 127.2 0.0083
Endpoint HbA1c <7 % and no symptomatic  
hypoglycemia
9.6 2.1 43.7 0.0036 15.6 2.0 123.7 0.0093
Endpoint HbA1c <7 % and no weight gain  
and no symptomatic hypoglycemia
7.4 1.6 32.2 0.0114 9.5 1.2 77.7 0.0356
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Table 4 Summary of  meta-analysis outcomes for  Japanese type 2 diabetes patients with  short (<10  years) and  long 
(≥10 years) duration of diabetes
FPG fasting plasma glucose, PPG postprandial glucose
Outcome Effect  
estimate
95 % Confidence limits p value Effect  
estimate
95 % Confidence limits p value
Lower Upper Lower Upper
Short (<10 years)  
duration of diabetes
Long (≥10 years)  
duration of diabetes
Change in HbA1c (%) −1.28 −1.65 −0.91 <0.0001 −0.93 −1.18 −0.67 <0.0001
Change in weight (kg) −0.56 −1.34 0.21 0.16 −0.09 −0.66 0.47 0.75
Change in FPG (mg/dL) −12.7 −26.6 1.2 0.07 −12.6 −24.9 −0.4 0.0438
Change in PPG: meal test (mg/dL) −152.6 −182.0 −123.2 <0.0001 −147.9 −176.8 −119.0 <0.0001
Odds  
ratio
95 % Confidence limits p value Odds  
ratio
95 % Confidence limits p value





Symptomatic hypoglycemia 5.2 1.5 18.7 0.0107 2.1 0.8 5.2 0.11
Severe hypoglycemia 0.0 0.0 0.0 – 0.0 0.0 0.0 –
Endpoint HbA1c <7 % 32.1 4.2 246.6 0.0009 8.9 2.5 31.9 0.0008
Endpoint HbA1c <7 % and no weight gain 22.5 2.9 174.3 0.0028 6.3 1.7 23.3 0.0057
Endpoint HbA1c <7 % and no symptomatic  
hypoglycemia
19.8 2.6 153.5 0.0043 9.0 2.0 41.1 0.0046
Endpoint HbA1c <7 % and no weight gain  
and no symptomatic hypoglycemia
11.6 1.4 93.3 0.0213 7.5 1.6 34.7 0.0099
Table 5 Summary of meta-analysis outcomes for Japanese type 2 diabetes patients <65 and ≥65 years of age
FPG fasting plasma glucose, PPG postprandial glucose
Outcome Effect  
estimate
95 % Confidence limits p value Effect  
estimate
95 % Confidence limits p value
Lower Upper Lower Upper
<65 years of age ≥65 years of age
Change in HbA1c (%) −1.00 −1.29 −0.72 <0.0001 −1.24 −1.55 −0.92 <0.0001
Change in weight (kg) −0.15 −1.07 0.76 0.74 −0.58 −1.39 0.22 0.16
Change in FPG (mg/dL) −11.2 −23.3 0.9 0.07 −14.8 −29.9 0.3 0.06
Change in PPG: meal test (mg/dL) −138.1 −177.0 −99.2 <0.0001 −166.5 −228.3 −104.6 <0.0001
Odds  
ratio
95 % Confidence limits p value Odds  
Ratio
95 % Confidence limits p value
Lower Upper Lower Upper
<65 years of age ≥65 years of age
Symptomatic hypoglycemia 2.3 1.0 5.6 0.06 5.1 1.3 19.7 0.0197
Severe hypoglycemia 0.0 0.0 0.0 – 0.0 0.0 0.0 –
Endpoint HbA1c <7 % 13.1 3.4 50.7 0.0002 23.2 4.1 131.9 0.0004
Endpoint HbA1c <7 % and no weight gain 8.4 2.1 33.8 0.0026 16.7 2.9 95.7 0.0015
Endpoint HbA1c <7 % and no symptomatic  
hypoglycemia
14.0 2.6 76.8 0.0023 12.3 2.1 70.7 0.0049
Endpoint HbA1c <7 % and no weight gain  
and no symptomatic hypoglycemia
7.8 1.3 45.6 0.0221 10.1 1.7 58.3 0.0100
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−228.3, −104.6, p  <  0.0001) in comparison to placebo 
treated patients ≥65  years of age. Lixisenatide treated 
patients ≥65 years of age had a greater likelihood of hav-
ing symptomatic hypoglycemia during the trial periods in 
comparison to placebo treated patients (OR 5.1, CI 1.3, 
19.7, p =  0.0197); however, lixisenatide treated patients 
had greater likelihoods of achieving an endpoint HbA1c 
<7 % (OR 23.2, CI 4.1, 131.9, p = 0.0004), and the com-
posite endpoints of an HbA1c <7 % and no weight gain 
(OR 16.7, CI 2.9, 95.7, p = 0.0015), an HbA1c <7 % and 
no symptomatic hypoglycemia (OR 12.3, CI 2.1, 70.7, 
p = 0.0049), and an HbA1c <7 % and no weight gain and 
no symptomatic hypoglycemia (OR 10.1, CI 1.7, 58.3, 
p  =  0.0100) in comparison to placebo treated patients 
≥65 years of age.
Discussion
The findings of the meta-analyses of the GetGoal-L-Asia 
and -S trials showed that among all Japanese type 2 dia-
betes patient subgroups examined lixisenatide add-on 
treatment vs. placebo was associated with significant 
reductions in HbA1c and PPG levels during the trial peri-
ods. The estimated differences in the change in HbA1c 
between lixisenatide and placebo treatment arms across 
the Japanese patient subgroups ranged from −0.80 to 
−1.28  %. The changes in HbA1c among the subgroups 
were similar to that observed for the overall Japanese 
populations of the GetGoal-L-Asia and -S trials (Get-
Goal-L-Asia: −1.1  %; GetGoal-S: −1.1  %) [14, 15]. The 
estimated differences in PPG levels between lixisenatide 
and placebo treatment arms across the subgroups ranged 
from −132.0 to −166.5  mg/dL and were also similar to 
that of the overall Japanese populations of the GetGoal-
L-Asia and -S trials (GetGoal-L-Asia: −155.7  mg/dL; 
GetGoal-S: −153.3  mg/dL) [14, 15]. The impact of lixi-
senatide add-on treatment among Japanese patients with 
type 2 diabetes was greater than that reported in a meta-
analysis of 14 randomized control trials that included 
patients with diabetes from multiple countries [16]. This 
meta-analysis reported that compared to placebo, lixi-
senatide significantly reduced HbA1c by −0.52  % and 
PPG level by −82  mg/dL [16]. The effect of lixisenatide 
treatment on PPG levels was similar to that observed 
among Japanese patients in the short-term PDY6797 
study (−160.3 mg/dL) [17]. FPG levels were only signifi-
cantly reduced among lixisenatide vs. placebo treated 
Japanese type 2 diabetes patients who had a baseline 
HbA1c ≥8 % or a ≥10 year duration of diabetes; however, 
there was a trend for FPG reduction in all other lixisena-
tide treated arms of subgroups.
As the effects of lixisenatide treatment on FPG lev-
els were modest among the subgroups of Japanese type 
2 diabetes patients it appears the much greater impact 
of lixisenatide add-on treatment on PPG levels pro-
vides the predominate benefit to greater HbA1c con-
trol. Wang et al. (2011) did report that the contribution 
of PPG to excess hyperglycemia is greater than FPG 
in well-controlled Asian type 2 diabetes patients and 
equally important as FPG in moderately to poorly con-
trolled Asian type 2 diabetes patients [18]. The substan-
tial lowering of PPG level associated with lixisenatide 
treatment may also potentially provide a cardiovascular 
benefit among Japanese type 2 diabetes patients [15, 17]. 
A long-term evaluation of the Kumamoto study, which 
included 110 Japanese type 2 diabetes patients found 
that intensive glycemic control, which included a thresh-
old of a 2-h PPG <180 mg/dL, along with thresholds of 
FPG <110 mg/dL and HbA1c <6.5 % can delay the onset 
and progression of microvascular complications [19]. 
Some studies have shown that high PPG, independent 
of FPG, is associated with cardiovascular morbidity and 
mortality among patients with type 2 diabetes, although 
others, notably interventional clinical trials, are conflict-
ing [20, 21]. A recently published study of 775 Japanese 
Americans did find that temporary hyperglycemia was 
correlated with oxidative stress, which likely plays a role 
in diabetic vascular complications [22, 23]. Addition-
ally, a cross-sectional study of Chinese type 2 diabetes 
patients using continuous glucose monitoring demon-
strated glycemic variability is associated with subclini-
cal atherosclerosis [24]. The influence of lixisenatide on 
macrovascular complications among patients with type 
2 diabetes and acute coronary syndrome was recently 
evaluated in the multicenter ELIXA study (Evaluation of 
Cardiovascular Outcomes in Patients with Type 2 Dia-
betes after Acute Coronary Syndrome During Treatment 
with AVE0010 [Lixisenatide], NCT01147250), which 
reported that the risk for major cardiovascular events 
was not significantly impacted by adding lixisenatide to 
usual care [25]. As optimal glycemic control has been 
shown to have a more pronounced effect on reducing 
the risk for microvascular complications among patients 
with type 2 diabetes it will be important in future studies 
to also examine whether lixisenatide treatment is associ-
ated with reduced risk for the development of microvas-
cular complications [26].
Lixisenatide add-on treatment vs. placebo was associ-
ated with a greater likelihood of symptomatic hypogly-
cemia during trial periods for Japanese type 2 diabetes 
patients who had a baseline HbA1c ≥8  %, or a low or 
high baseline BMI, or a diabetes duration <10  years, or 
who were ≥65  years of age. However, among all sub-
groups evaluated lixisenatide add-on treatment vs. pla-
cebo was associated with significantly greater odds for 
achieving an HbA1c <7 % at the end of the trial periods 
and achieving the glycemic target without symptomatic 
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hypoglycemia. There were no severe hypoglycemia events 
observed among the Japanese populations of these two 
trials indicating that the hypoglycemia differences were 
related to non-severe hypoglycemia frequency.
Among the overall Japanese GetGoal-L-Asia and -S 
trial populations lixisenatide treatment was associ-
ated with a beneficial effect on body weight, with mean 
reductions of −0.85  kg and −1.12  kg respectively [14, 
15]. In our meta-analysis of the subgroups of Japanese 
type 2 diabetes patients from these two trials lixisena-
tide treatment also tended to be associated with weight 
loss, although the reductions were not statistically sig-
nificant vs. placebo. In the GetGoal-L- Asia and -S trials 
type 2 diabetes patients were treated with basal insulin 
and/or sulfonylurea, both of which are associated with 
weight gain [10, 11]. Thus, our results are consistent with 
the theory that lixisenatide treatment mitigates weight 
gain caused by basal insulin and/or sulfonylurea treat-
ment. Furthermore, lixisenatide vs. placebo treatment 
was associated with a much greater likelihood of achiev-
ing an endpoint HbA1c <7  % without weight gain dur-
ing the trial periods across all subgroups evaluated (odds 
ratios: 6.3–22.5). Japanese patients with type 2 diabetes 
and ≥65 years of age treated with lixisenatide vs. placebo 
had a 16.7-fold greater likelihood for having an endpoint 
HbA1c <7 % and no weight gain. As type 2 diabetes is a 
risk factor for sarcopenia/frailty (i.e., progressive loss of 
muscle mass and strength) and prevalent among elderly 
persons, good glycemic control along with weight loss 
may prevent its progression [27, 28].
This meta-analyses was conducted on specific sub-
groups from a limited number of trials, which potentially 
may have led to reduced statistical power to detect dif-
ferences in treatment arms of subgroups. Although the 
intent of this study was to specifically evaluate the effects 
of lixisenatide add-on treatment among Japanese type 2 
diabetes patients, this also made the results less applica-
ble to other type 2 diabetes patient populations. In the 
GetGoal-L- Asia and -S trials type 2 diabetes patients 
were treated with different anti-diabetic drugs (i.e., differ-
ent basal insulins, metformin, sulfonylureas) at different 
dosages in combination with lixisenatide or placebo [10, 
11]. Differences in combinations and dosages of anti-dia-
betic medications may influence the outcomes, such as 
weight change, of the two trial populations. However, the 
randomized nature of the design of these trials may par-
tially ameliorate such differences between the trial arms 
of each respective trial [10, 11]. Furthermore, also largely 
explained by randomization of the trial populations, are 
the generally similar baseline HbA1c values, FPG levels, 
and PPG levels of the trials arms of the GetGoal-L-Asia 
and -S trials [10, 11]. For example, baseline HbA1c values 
of type 2 diabetes patients in the GetGoal-L-Asia trial 
were 8.54 and 8.52 % for patients in the lixisenatide and 
placebo add-on trials arms, respectively [10]. This was 
also true among type 2 diabetes patients treated with lixi-
senatide and placebo add-on treatment in the GetGoal-S 
trial, which were 8.3 and 8.2 %, respectively [11].
For this study we examined several patient subgroups 
to better understand the utility of lixisenatide add-on 
treatment for improving glycemic control among Japa-
nese type 2 diabetes patients with different characteris-
tics. Although, the results of the meta-analyses show that 
regardless of baseline HbA1c level, baseline BMI, dura-
tion of diabetes, or age, add-on of lixisenatide treatment 
was associated with improvement in glycemic control 
and other outcomes, there were differences in the size of 
the effect. Additionally, other factors than evaluated in 
our meta-analyses, such as baseline FPG and PPG lev-
els, may also influence response to treatment with anti-
diabetic medications and further study is warranted. 
The interaction of certain characteristics of type 2 diabe-
tes patients, like that of BMI and HbA1c level, may also 
influence responses to treatments and outcomes of type 2 
diabetes patients. Further research is needed to evaluate 
the potential interactions of such factors, and how these 
outcomes might be translated into the real-world of Japa-
nese patients with type 2 diabetes. Moreover, it will be 
important to study patients with certain characteristics 
for longer periods of time in the real-world setting, espe-
cially in regard to the risk for developing microvascular 
and macrovascular complications. Lastly, the results of 
the clinical trial meta-analysis are limited by the patient 
types and trial designs as evaluated in the GetGoal-L-
Asia and -S trials, of which the former did not include 
reporting of detailed data on outcomes, such as changes 
in blood pressure. Additionally, this meta-analysis did 
not evaluate other adverse events, except hypoglycemia.
Conclusion
Among Japanese type 2 diabetes patients, regardless of 
HbA1c level, BMI, duration of diabetes, or age, lixisena-
tide may be an efficacious and a safe add-on therapy, 
when hypoglycemia risk is taken into consideration, lead-
ing to improved glycemic outcomes.
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